详情页 - 首都医科大学宣武医院知识库

当前位置：首页 > 详情页

Platelets in Acute Coronary Syndrome Patients with High Platelet Reactivity after Dual Antiplatelet Therapy Exhibit Upregulation of miR-204-5p

文献详情

资源类型：

作者：

机构： [a]Department of Clinical Laboratory, Beijing An Zhen Hospital, Capital Medical University, China [b]Department of Clinical Laboratory, Beijing An Zhen Hospital, Capital Medical University, China [c]Department of Cardiology, Beijing An Zhen Hospital, Capital Medical University, China [d]Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical, China [e]Beijing Lab for Cardiovascular Precision Medicine, Beijing, China

出处：

ISSN：

关键词： acute coronary syndrome biomarker dual antiplatelet therapy microRNA platelet reactivity

摘要：

Acute coronary syndrome (ACS) patients treated with dual antiplatelet therapy (DAPT) show individual differences in platelet reactivity (PR). Here, we aim to find differences in the platelet microRNA (miRNA) expression profiles of high PR and low PR patients to serve as potential biomarkers. ADP-induced platelet aggregation (PAG) was used to determine PR. High-throughput sequencing technology was used to profile differentially expressed platelet miRNAs in high PR (PAG>50%) and low PR (PAG≤50%) patients. We used real-time quantitative reverse transcription-polymerase chain reactions (RT-qPCR) to validate the sequencing results. Finally, we statistically evaluated the diagnostic value of the miRNAs and explored their molecular function using bioinformatic analysis. The results show that miR-204-5p was confirmed to be significantly upregulated in the high PR group. The area under the ROC curve (AUC) of miR-204-5p was 0.667, and its expression significantly correlated with the Gensini score. Stepwise binary logistic regression analysis suggested that miR-204-5p expression level was an independent predictor of PR. Furthermore, bioinformatic analysis showed that miR-204-5p may be associated with platelet synapse formation and platelet vesicle release. Our data indicates that platelet miR-204-5p may serve as a novel biomarker of PR to guide treatment with antiplatelet drugs. © 2019 by the Association of Clinical Scientists, Inc.

语种：

中科院(CAS)分区：

出版当年[2018]版：

大类 | 4 区医学

小类 | 4 区医学实验技术

最新[2023]版：

大类 | 4 区医学

小类 | 4 区医学实验技术

第一作者：

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]Platelets in Acute Coronary Syndrome Patients with High Platelet Reactivity after Dual Antiplatelet Therapy Exhibit Upregulation of miR-204-5p. [2]急性冠脉综合征双联抗血小板治疗合并出血的防治 [3]Comparison of Dual Antiplatelet Therapy with Clopidogrel and Ticagrelor in Patients with Acute Coronary Syndrome at High Risk of Bleeding [4]Impact of Obstructive Sleep Apnea on Platelet Function Profiles in Patients With Acute Coronary Syndrome Taking Dual Antiplatelet Therapy [5]In-hospital outcomes of dual loading antiplatelet therapy in patients 75 years and older with acute coronary syndrome undergoing percutaneous coronary intervention: Findings from the CCC-ACS (Improving Care for Cardiovascular Disease in China-acute coronary syndrome) project [6]Gender-related differences in post-discharge bleeding among patients with acute coronary syndrome on dual antiplatelet therapy: A BleeMACS sub-study [7]Risk of hemorrhagic and ischemic stroke for dual antiplatelet therapy and new generation oral anticoagulants in patients with acute coronary syndrome [8]血栓弹力图评价急性冠状动脉综合征患者介入术后血小板高反应性对不良预后影响分析 [9]TRIPLE VERSUS DUAL ANTIPLATELET THERAPY IN PATIENTS WITH [10]Dual antiplatelet therapy in stroke and ICAS Subgroup analysis of CHANCE